Accelerated Partial Breast Irradiation (APBI) For HER2+ Early-Stage Breast Cancer

D. A. Roth O'Brien, L.A. Boe, B.A. Mueller,J. Cuaron,A.J. Xu, M.B. Bernstein,B. McCormick,S.N. Powell,A.J. Khan,L.Z. Braunstein

International journal of radiation oncology, biology, physics（2023）

Cited 0|Views3

No score

Abstract

Among a cohort of HER2+ early-stage breast cancer patients managed with BCS and APBI, we observed a 2-year LR rate of 3.8% with no regional or distant recurrences, and excellent overall survival. These findings merit longer term follow-up among larger cohorts, although are thus far consistent with the results of contemporary randomized trials of APBI unselected for HER2-status.

Translated text

Key words

accelerated partial breast irradiation,breast cancer,her2+,apbi,early-stage

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined